These medications are beneficial for those with chronic hives who don’t respond to antihistamines alone. They’re usually ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

"Celltrion files XOLAIR biosimilar for chronic spontaneous urticaria BLA" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...

The drug was subsequently granted marketing authorization to treat chronic spontaneous urticaria and rhinosinusitis with nasal polyps in certain patients. For its new indication, Xolair’s safety ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

The urticaria market is currently dominated by Xolair (omalizumab), which has achieved over $1 billion in revenue. However, Xolair's market penetration has been limited due to safety concerns ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...